Pharmacology of triptans

Bibliography

• SAXENA PR, DE VRIES P, VILLALON CM: 5-HTI-like receptors: a time to bid goodbye. Trends Pharmacol. Sci. (1998) 19:311–316.
   PubMed Web of Science ®Google Scholar
• ••Review of the nomenclature of 5-HT1-like receptors.
   Google Scholar
• Saxena PR, Wallis DI, Wouters W, Bevan P (Eds.), Kluwer academic publishers, Dordrecht, The Netherlands (1990):416–431.
   Google Scholar
• ••Review about the discovery of sumatriptan.
   Google Scholar
• SAXENA PR, FERRARI MD: From serotonin receptor classification to the antimigraine drug sumatriptan. Cephalalgia (1992) 12:187–196.
   PubMed Web of Science ®Google Scholar
• HAGAN JJ, SLADE PD, GASTER L, et al.: Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig. Eur. J. Pharmacol. (1997) 331:169–174.
   PubMed Web of Science ®Google Scholar
• DE VRIES P, SANCHEZ-LOPEZ A, CENTURION D, et al.: The canine external carotid vasoconstrictor 5-HT1 receptor: blockade by 5-HT1B (SB-224289), but not by 5-HT1p (BRL15572) receptor antagonists. Eur. J. Pharmacol. (1998) 362:69–72.
   PubMed Web of Science ®Google Scholar
• •First report of 5-HT1B receptors mediating sumatriptan-induced vasoconstriction in vivo.
   Google Scholar
• VERHEGGEN R, HUNDESHAGEN AG, BROWN AM, SCHINDLER M, KAUMANN AJ: 5-HTIB receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br. J. Pharmacol. (1998) 124:1345–1354.
   PubMed Web of Science ®Google Scholar
• •First report of 5-HT1B receptors mediating sumatriptan-induced vasoconstriction in vitro.
   Google Scholar
• FERRARI MD: Migraine. Lancet (1998) 351:1043–1051.
   PubMedGoogle Scholar
• ••Recent review on migraine.
   Google Scholar
• GOADSBY PJ: Serotonin 5-ffr1si1D receptor agonists in migraine. Comparative pharmacology and its therapeuthic implications. CNS Drugs (1998) 10:271–286.
   Web of Science ®Google Scholar
• ••Another recent review on migraine.
   Google Scholar
• LEYSEN JE, GOMMEREN W, HEYLEN L, et al.: Alniditan, a new 5-hydroxytryptaminem agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptaminema, human 5-hydroxytryptaminemB, and calf 5-hydroxytryptaminem receptors investigated with [s1-1]5-hydroxytryptamine and [3H]alniditan. Mol. Pharmacol. (1996) 50:1567–1580.
   PubMed Web of Science ®Google Scholar
• MARTIN GR, ROBERTSON AD, MACLENNAN SJ, et al.: Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1nD receptor partial agonist, 311C90 (zolmitriptan). Br. J. Pharmacol. (1997) 121:157–164.
   PubMed Web of Science ®Google Scholar
• BOU J, DOMENECH T, GRAS J, et al.: Pharmacological profile of almotriptan, a novel antimigraine agent. Cephalalgia (1997) 17:421.
   Google Scholar
• PARSONS AA, RAVAL P, SMITH S, et al.: Effects of the novel high-affinity 5-HT0B/1pyreceptor ligand frovatriptan in human isolated basilar and coronary arteries. J. Cardiovasc. Pharmacol. (1998) 32: 220–290.
   PubMed Web of Science ®Google Scholar
• PAUWELS PJ, PALMIER C, TARDIF S, et al.: F11356, a new 5-HT derivative, with selective, potent and highly efficacious agonist properties at 5-HT1ni1D receptors. Naunyn-Schmiedebrg's Arch. Pharmacol. (1998) 358:R523.
   Google Scholar
• RANCE D, CLEAR N, DALLMAN L: Physicochemical comparison of eletriptan and other 5-HT1D-like agonists as a predictor of oral absoption potential. Headache (1997) 17:328.
   Google Scholar
• FOWLER PA, LACEY LF, THOMAS M, et al.: The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur. Neurol. (1991) 31:291–294.
   PubMed Web of Science ®Google Scholar
• LACEY LF, HUSSEY EK, FOWLER PA: Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur. J. Clin. Pharmacol. (1995) 47:543–548.
   PubMed Web of Science ®Google Scholar
• PECK RW, SEABER EJ, DIXON RM, et al.: The pharmacodynamics and pharmacokinetics of the 5HT1Barragonist zolmitriptan in healthy young and elderly men and women. Clin. Pharmacol. Ther. (1998) 63:342–353.
   PubMed Web of Science ®Google Scholar
• KEMPSFORD RD, BAILLE P, FUSEAU E: Oral naratriptan (2.5-10 mg) exhibit dose-proportional pharmacokinetics. Cephalalgia (1997) 17:408.
   Google Scholar
• FUSEAU E, BAILLE P, KEMPSFORD RD: A study to determine the absolute oral bioavailability of naratriptan. Cephalalgia (1997) 17:417.
   Google Scholar
• LEE Y, ERMLICH SJ, STERRETT AT, et al.: Pharmacokinetics and tolerability of intravenous rizatriptan in healthy females. Biopharm. Drug Dispos. (1998) 19: 577–581.
   PubMed Web of Science ®Google Scholar
• SCIBERRAS DG, POLVINO WJ, GERTZ BJ, et al.: Initial human experience with MK-462 (rizatriptan): a novel 5-HTID agonist. Br. J. Clin. Pharmacol. (1997) 43:49–54.
   PubMed Web of Science ®Google Scholar
• CHENG H, POLVINO WJ, SCIBERRAS D, et al.: Pharmacokinetics and food interaction of MK-462 in healthy males. Biopharm. Drug Dispos. (1996) 17:17–24.
   PubMed Web of Science ®Google Scholar
• MILTON KA, BUCHANAN TJ, HAUG-PIHALE G, MOLZ KH: The pharmacokinetics, safety and tolerability of oral eletriptan in subjects with impaired hepatic function. Cephalalgia (1998) 18:411–412.
   Google Scholar
• HYLAND R, JONES BC, MCCLEVERTY P, MITCHELL RJ, MORGAN P: In vitro metabolism of eletriptan in human liver microsomes. Cephalalgia (1998) 18:404.
   Google Scholar
• MORGAN P, RANCE D, JAMES G, MITCHELL R, MILTON A: Comparative absorption and elimination of eletriptan in rat, dog and human. Cephalalgia (1997) 17:414.
   Google Scholar
• ROBERT M, WARRINGTON SJ, ZAYAS JM, et al.: Electrocardiographic effects and pharmacokinetics of oral almotriptan in healthy subjects. Cephalalgia (1998) 18:406.
   Google Scholar
• CABAROCCAS X, SALVA M: Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia (1997) 17:421.
   Google Scholar
• BUCHAN P, KEYWOOD C, WARD C: The pharmacokinetics of frovatriptan (VML 251/SB 209509), a potent, selective 5-HT(B/1) agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteers. Annual Meeting of the American Association for the Study of Headache. San Fransisco, USA (1998).
   Google Scholar
• DUQUESNOY C, MAMET JP, SUMNER D, FUSEAU E: Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur. J. Pharm. Sci. (1998) 6:99–104.
   PubMed Web of Science ®Google Scholar
• MACINTYRE PD, BHARGAVA B, HOGG KJ, GEMMILL JD, HILLIS WS: Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation (1993) 87:401–405.
   PubMed Web of Science ®Google Scholar
• PAGNIEZ F, VALENTIN JP, VIEU S, COLPAERT FC, JOHN GW: Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat. Br. J. Pharmacol. (1998) 123:205–214.
   PubMed Web of Science ®Google Scholar
• CAEKEBEKE JF, FERRARI MD, ZWETSLOOT CP, JANSEN J, SAXENA PR: Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology (1992) 42:1522–1526.
   PubMed Web of Science ®Google Scholar
• CONNOR HE, FENIUK W, BEATTIE DT, et al.: Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia (1997) 17:145–152.
   PubMed Web of Science ®Google Scholar
• Edvinsson L (Ed.), Martin Dunitz Ltd., London, UK (1999) :119–132.
   Google Scholar
• MACLENNAN SJ, CAMBRIDGE D, WHITING MV, MARSTON C, MARTIN GR: Cranial vascular effects of zolmitriptan, a centrally active 5 -HTiBim receptor partial agonist for the acute treatment of migraine. Eur. J. Pharmacol. (1998) 361:191–197.
   PubMed Web of Science ®Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, BAKER R, et al.: In vivo pharmacology of the novel 5-HT1p receptor agonist MK-462. Cephalalgia (1995) 15:204.
   Google Scholar
• GUPTA P, BROWN D, BUTLER P, et al.: Pre-clinical in vivo pharmacology of eletriptan (UK-116,044): a potent and selective partial agonist at `5-HT1D-like' receptors. Cephalalgia (1996) 16:386.
   Google Scholar
• PARSONS AA, PARKER SG, RAVAL P, et al.: Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs. J. Cardiovasc. Pharmacol. (1997) 30:136–141.
   PubMed Web of Science ®Google Scholar
• JOHN GW, VERSCHEURE Y, INFANTI F, et al.: In vivo pharmacological actions of F11356, a novel high efficacy 5-HT1Bm receptor agonist. Naunyn-Schmiedebergs's Arch. Pharmacol. (1998) 358:R523.
   Google Scholar
• SPERLING B, TFELT-HANSEN P, LINES C: Lack of effect of MK-462 on cerebral blood flow in humans. Cephalalgia (1995) 15:206.
   Google Scholar
• HEYCK H: Pathogenesis of migraine. Res. Clin. Stud. Headache (1969) 2:1–28.
   Google Scholar
• ••Early review implicating AVA in migraine pathophysiology.
   Google Scholar
• Olesen J, Moskowitz MA (Eds.), Lippincott-Raven Publishers, Philadelphia, USA (1995) :189–198.
   Google Scholar
• •Recent review on AVAs and migraine pathophysiology.
   Google Scholar
• VAN ES NM, BRUNING TA, CAMPS J, et al.: Assessment of peripheral vascular effects of antimigraine drugs in humans. Cephalalgia (1995) 15:288–291.
   PubMed Web of Science ®Google Scholar
• CASTRO ME, ROMON T, CASTILLO MJ, et al.: Identification and characterization of a new serotonergic recognition site with high affinity for 5-carboxamidotryptamine in mammalian brain. J. Neurochem. (1997) 69:2123–2131.
   PubMed Web of Science ®Google Scholar
• PARSONS AA, RAVAL P, SMITH S, et al.: Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J. Cardiovasc. Pharmacol. (1998) 32:220–224.
   PubMed Web of Science ®Google Scholar
• MARTIN GR: Inhibition of the trigemino-vascular system with 5-HT1p agonist drugs: selectively targeting additional sites of action. Eur. Neurol. (1996) 36:13–18.
   PubMedGoogle Scholar
• •Review on central effects by antimigraine drugs.
   Google Scholar
• GUPTA P, NAPIER JS, SHEPPERSON NB, WALLIS R: Further characterization of the in vitro pharmacology of eletriptan. Cephalalgia (1997) 17:413.
   Google Scholar
• LONGMORE J, RAZZAQUE Z, SHAW D, et al.: Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br. J. Clin. Pharmacol (1998) 46: 577–582.
   PubMed Web of Science ®Google Scholar
• GUPTA P, SCATCHARD J, NAPIER C, MCHARG A, WALLIS R: Characterisation of the contractile activity of eletriptan at the canine vascular 5-HT1B receptor. Eur. J. Pharmacol. (1999) 367: 283–290.
   PubMed Web of Science ®Google Scholar
• BEER MS, MIDDLEMISS DN, STANTON JA, et al.: In vitro pharmacological profile of the novel 5-HTID receptor agonist MK-462. Cephalalgia (1995) 15:203.
   Google Scholar
• JOHN GW, VALENTIN JP, LEGRAND B, et al.: In vitro vascular and neuronal actions of F11356, a novel high efficacy 5-HT1Bm receptor agonist, in models relevant to migraine. Naunyn-Schmiedebergs's Arch. Pharmacol. (1998) 358:R523.
   Google Scholar
• MAASSENVANDENBRINK A, REEKERS M, BAX WA, FERRARI MD, SAXENA PR: Coronary side-effect potential of current and prospective antimigraine drugs. Circulation (1998) 98:25–30.
   PubMed Web of Science ®Google Scholar
• •Investigation of the human coronary side-effects of sumatriptan and second-generation triptans.
   Google Scholar
• CONNOR HE, FENIUK W, HUMPHREY PP: 5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation. Eur. J. Pharmacol. (1989) 161:91–94.
   PubMed Web of Science ®Google Scholar
• •Report on 5-HT receptors mediating human coronary artery constriction.
   Google Scholar
• MOSKOWITZ MA: Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci. (1992) 13:307–311.
   PubMed Web of Science ®Google Scholar
• ••Review on neurogenic inflammation theory.
   Google Scholar
• WILLIAMSON DJ, SHEPHEARD SL, HILL RG, HARGREAVES RJ: The novel antimigraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol. (1997) 328:61–64.
   PubMed Web of Science ®Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, BEER MS, HILL RG, HARGREAVES RJ: Differential effects of 5-HT1nD receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology (1997) 36:525–533.
   PubMed Web of Science ®Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, WILLIAMS J, HILL RG, HARGREAVES RJ: Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology (1995) 34:255–261.
   PubMed Web of Science ®Google Scholar
• CUMBERBATCH MJ, HILL RG, HARGREAVES RJ: The effects of 5-HT1A, 5-HT1B and 5-HT1p receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Eur. J. Pharmacol. (1998) 362:43–46.
   PubMed Web of Science ®Google Scholar
• YU XJ, CUTRER FM, MOSKOWITZ MA, WAEBER C: The 5-HTE) receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology (1997) 36:83–91.
   PubMed Web of Science ®Google Scholar
• ENNIS MD, GHAZAL NB, HOFFMAN RL, et al.: Isochroman-6-carboxamides as highly selective 5-HTID agonists: potential new treatment for migraine without cardiovascular side effects. J. Med. Chem. (1998) 41:2180–2183.
   PubMed Web of Science ®Google Scholar
• •First report on a selective 5-HT1p receptor agonist.
   Google Scholar
• PHEBUS LA, JOHNSON KW, ZGOMBICK JM, et al.: Characterization of LY 344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci. (1997) 61:2117–2126.
   PubMed Web of Science ®Google Scholar
• JOHNSON KW, SCHAUS JM, DURKIN MM, et al.: 5-HTIF receptor agonists inhibit neurogenic dural inflammation in guinea pigs. NeuroReport (1997) 8:2237–2240.
   PubMed Web of Science ®Google Scholar
• •First report on 5-HT1F receptor agonists.
   Google Scholar
• ROON K, DIENER HC, ELLIS P, et al.: CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical trials. Cephalalgia (1997) 17:245.
   Google Scholar
• PARSONS AA: Recent advances in mechanisms of spreading depression. Curr. Opin. Neurol. (1998) 11:227–231.
   PubMed Web of Science ®Google Scholar
• •Recent review on cortical spreading depression and migraine.
   Google Scholar
• CHAN WN, EVANS JN, HADLEY MS, et al.: Identification of (-)-cis-6-acety1-4S-(3-chloro-4-fluoro-benzoylamino)3,4-dihydro-2,2-dimethy1-2H-benzo [b]pyran-3S-ol as a potential antimigraine agent. Bioorg. Med. Chem. Lett. (1999) 9:285–290.
   PubMed Web of Science ®Google Scholar